Meeting
2022 ASCO Annual Meeting
Germline predisposition in oncologic and dermatologic melanoma cohorts.
Authors
Pauline Funchain
Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH
Pauline Funchain , Ying Ni , Brandon Bungo , Brandie Heald , Michelle Arbesman , Tapas Ranjan Behera , Sarah M. Nielsen , Shelley McCormick , Jung Min Song , Emily Nizialek , Brian Gastman , Edward D. Esplin , Mykyta Artomov , Hensin Tsao , Joshua Arbesman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10523)
DOI
10.1200/JCO.2022.40.16_suppl.10523
Abstract #
10523
Poster Bd #
401
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Tumor sequencing with germline genetic testing: Identification of patients with hereditary cancer and precision treatment eligibility.
First Author: Scott T. Michalski
Poster
2018 ASCO Annual Meeting
Multiplex germline testing in selected melanomas presenting to oncology clinic.
First Author: Pauline Funchain
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Molecular genetic sequencing of neuroendocrine tumors of the gastrointestinal tract.
First Author: Alexandra Androsova
Poster
2020 ASCO Virtual Scientific Program
Development and validation of the PREMMplus clinical prediction model for multigene hereditary cancer risk assessment.
First Author: Matthew B. Yurgelun